Olsutamig is a bivalent humanized IgG4kappa monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. It is capable of binding simultaneously to PSMA on tumor cell surfaces and CD3E on T cell surfaces, leading to significant activation of T cells and the specific destruction of prostate cancer cells.
CAS Nummer:
[3034664-43-9]
Target-Kategorie:
PSMA|||Integrin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
